Combined-modality therapy in locally advanced primary rectal cancer

被引:38
|
作者
Ratto, C
Valentini, V
Morganti, AG
Barbaro, B
Coco, C
Sofo, L
Balducci, M
Gentile, PC
Pacelli, F
Doglietto, GB
Picciocchi, A
Cellini, N
机构
[1] Catholic Univ, Dept Surg Sci, I-00168 Rome, Italy
[2] Catholic Univ, Dept Radiotherapy, I-00168 Rome, Italy
[3] Catholic Univ, Dept Radiol, I-00168 Rome, Italy
关键词
locally advanced rectal cancers; prognostic factors; combined therapies; continuous infusion; 5-fluorouracil; mitomycin C; external radiation therapy; intraoperative radiotherapy;
D O I
10.1007/s10350-004-6497-1
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PURPOSE: Patients with unresectable, locally advanced rectal cancer are reported to have a dismal prognosis. The aim of this study was to analyze the effect of combined-modality therapy on clinical outcome. METHODS: From March 1990 to December 1997, 43 patients (28 males; median age, 62 years; median follow-up, 74 months) with locally advanced (T4 and/or N3) nonmetastatic rectal cancer received external-beam radiation (23.6 plus 23.6 Gy (split course), 8 patients; 45 Gy, 35 patients) plus 5-fluorouracil (96-hour continuous infusion, Days 1-4, at 1,000 mg/m(2)/day) and mitomycin C (10 mg/m(2), intravenous bolus, Day 1). Concomitant chemotherapy was repeated at the beginning of the second course (split-course group) or in the last week of radiotherapy (continuous-course group). After 6 to 8 weeks, patients were evaluated for surgical resection and intraoperative radiation therapy (10 to 15 Gy). Thereafter, adjuvant chemotherapy (5-fluorouracil plus leucovorin, 6-9 courses) was prescribed. RESULTS: During chemoradiation, 5 patients (11.6 percent) developed Grade 3 to 4 hematologic toxicity. After chemoradiation, 29 patients (67.4 percent) had an objective clinical response (complete response, 2.3 percent; partial response, 65.1 percent). Thirty-eight patients underwent radical surgery (anterior resection, 24 patients; abdominoperineal resection, 14 patients; intraoperative radiation therapy boost on the tumor bed, 19 patients), and 2 patients had partial tumor resection. No perioperative deaths occurred in the patient group. Five-year survival and local control rates were 59.9 and 69.1 percent, respectively. Distant metastasis occurred in 44.2 percent of patients. Statistically significant relationships between intraoperative radiation therapy and local control (P = 0.0104), radical surgery and survival (P = 0.0120), and adjuvant chemotherapy and disease-free survival (P = 0.0112) were observed. CONCLUSIONS: Our data suggest that combined-modality therapy was relatively well tolerated and resulted in good local control and survival. With regard to the impact of surgical resection on survival, additional studies aimed at improving the local response rate are necessary, whereas the positive impact of intraoperative radiotherapy on local control appears to justify the inclusion of this therapeutic modality in prospective multi-institutional trials.
引用
收藏
页码:59 / 67
页数:9
相关论文
共 50 条
  • [1] Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer
    Mitchell, EP
    [J]. ONCOLOGY-NEW YORK, 2000, 14 (12): : 56 - 59
  • [2] Role of Combined-Modality Therapy in the Management of Locally Advanced Rectal Cancer
    Hosein, Peter J.
    Rocha-Lima, Caio M.
    [J]. CLINICAL COLORECTAL CANCER, 2008, 7 (06) : 369 - 375
  • [3] Neoadjuvant Combined-Modality Therapy for Locally Advanced Rectal Cancer and Its Future Direction
    Salem, Mohamed E.
    Hartley, Marion
    Unger, Keith
    Marshall, John L.
    [J]. ONCOLOGY-NEW YORK, 2016, 30 (06): : 546 - +
  • [4] Combined-modality neoadjuvant therapy for rectal cancer
    O'Connell, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5450 - 5451
  • [5] Circulating proteins in response to combined-modality therapy in locally advanced rectal cancer identified by antibody array screening
    Kalanxhi, Erta
    Hektoen, Helga Helseth
    Meltzer, Sebastian
    Dueland, Svein
    Redalen, Kathrine Roe
    Flatmark, Kjersti
    Ree, Anne Hansen
    [J]. CANCER RESEARCH, 2015, 75
  • [6] Adjuvant postoperative combined-modality therapy for rectal cancer
    Minsky, BD
    [J]. ONCOLOGY-NEW YORK, 1999, 13 (07): : 132 - 135
  • [7] Evolving strategies for combined-modality therapy for locally advanced head and neck cancer
    Posner, Marshall
    [J]. ONCOLOGIST, 2007, 12 (08): : 967 - 974
  • [8] Primary combined-modality therapy for esophageal cancer
    Minsky, Bruce D.
    [J]. ONCOLOGY-NEW YORK, 2006, 20 (05): : 497 - 505
  • [9] Combined-modality therapy for rectal cancer using irinotecan
    Minsky, BD
    [J]. ONCOLOGY-NEW YORK, 2002, 16 (05): : 35 - 38
  • [10] Combined-modality therapy for rectal cancer: Future prospects
    Czito, Brian G.
    Willett, Christopher G.
    Bendell, Johanna C.
    [J]. CLINICAL COLORECTAL CANCER, 2007, 6 (09) : 625 - 633